Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.09M Buy
+75,000
New +$3.26M 0.7% 32
2026
Q1
– Sell
-21,000
Closed -$979K – 100
2025
Q4
$1.02M Buy
+21,000
New +$1.04M 0.27% 66
2025
Q1
– Sell
-14,500
Closed -$699K – 96
2024
Q4
$699K Buy
14,500
+3,500
+32% +$178K 0.34% 63
2024
Q3
$634K Hold
11,000
– – 0.25% 64
2024
Q2
$534K Hold
11,000
– – 0.27% 64
2024
Q1
$535K Hold
11,000
– – 0.26% 58
2023
Q4
$547K Buy
11,000
+1,100
+11% +$53.8K 0.3% 56
2023
Q3
$531K Hold
9,900
– – 0.29% 63
2023
Q2
$534K Hold
9,900
– – 0.28% 58
2023
Q1
$539K Sell
9,900
-4,600
-32% -$224K 0.33% 46
2022
Q4
$702K Buy
14,500
+3,492
+32% +$153K 0.47% 39
2022
Q3
$419K Buy
+11,008
New +$491K 0.27% 57

Other funds holding SNY

DCF Advisers's SNY Position: Q3 2026 in Review

DCF Advisers opened a new position in Sanofi (SNY) in Q3 2026: 75,000 shares worth $3.09M. The stake represents 0.7% of the portfolio and ranks #32 among its holdings. This is a return to the name: DCF Advisers previously reported a position in SNY as recently as Q4 2025.

DCF Advisers first reported a position in SNY in Q3 2022 and has held it in 12 quarters since. 421 funds tracked by Wall St. Rank hold SNY as of Q3 2026.

  • DCF Advisers held 75,000 shares of Sanofi worth $3.09M as of Q3 2026.
  • Sanofi was a new DCF Advisers position in Q3 2026.
  • Sanofi made up 0.7% of DCF Advisers's portfolio in Q3 2026, its #32 holding.
  • DCF Advisers first reported a position in Sanofi in Q3 2022 and has held it in 12 quarters since.
  • 421 funds tracked by Wall St. Rank held Sanofi as of Q3 2026.

Based on DCF Advisers's 13F filing for Q3 2026, filed 4 Nov 2026.